Home Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance
Article Publicly Available

Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance

  • Margaritis Avgeris , Konstantinos Mavridis and Andreas Scorilas EMAIL logo
Published/Copyright: May 1, 2012
Download Article (PDF)
Biological Chemistry
From the journal Biological Chemistry Volume 393 Issue 5

Received: 2011-11-11
Accepted: 2012-1-6
Published Online: 2012-05-01
Published in Print: 2012-05-01

©2012 by Walter de Gruyter Berlin Boston

Articles in the same Issue

  1. Guest Editorial
  2. Highlight: The 4th International Symposium on Kallikreins and Kallikrein-Related Peptidases
  4. Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance
  5. Epigenetic regulation of kallikrein-related peptidases: there is a whole new world out there
  6. Non-combinatorial library screening reveals subsite cooperativity and identifies new high-efficiency substrates for kallikrein-related peptidase 14
  7. One round of SELEX for the generation of DNA aptamers directed against KLK6
  8. Kallikrein 6 is a novel molecular trigger of reactive astrogliosis
  9. Characterization of SPINK9, a KLK5-specific inhibitor expressed in palmo-plantar epidermis
  10. The miRNA-kallikrein axis of interaction: a new dimension in the pathogenesis of prostate cancer
  11. Stromal cell-associated expression of kallikrein-related peptidase 6 (KLK6) indicates poor prognosis of ovarian cancer patients
  12. The kallikrein 14 gene is down-regulated by androgen receptor signalling and harbours genetic variation that is associated with prostate tumour aggressiveness
  13. Kallikrein-related peptidase signaling in colon carcinoma cells: targeting proteinase-activated receptors
  14. Proteinase-activated receptors (PARs): differential signalling by kallikrein-related peptidases KLK8 and KLK14
  15. Masthead
  16. Masthead
https://doi.org/10.1515/hsz-2011-0260
Keywords for this article
biomarkers; epithelial-mesenchymal transition; extracellular matrix proteases; KLK; PSA; serine proteases

Articles in the same Issue

  1. Guest Editorial
  2. Highlight: The 4th International Symposium on Kallikreins and Kallikrein-Related Peptidases
  4. Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance
  5. Epigenetic regulation of kallikrein-related peptidases: there is a whole new world out there
  6. Non-combinatorial library screening reveals subsite cooperativity and identifies new high-efficiency substrates for kallikrein-related peptidase 14
  7. One round of SELEX for the generation of DNA aptamers directed against KLK6
  8. Kallikrein 6 is a novel molecular trigger of reactive astrogliosis
  9. Characterization of SPINK9, a KLK5-specific inhibitor expressed in palmo-plantar epidermis
  10. The miRNA-kallikrein axis of interaction: a new dimension in the pathogenesis of prostate cancer
  11. Stromal cell-associated expression of kallikrein-related peptidase 6 (KLK6) indicates poor prognosis of ovarian cancer patients
  12. The kallikrein 14 gene is down-regulated by androgen receptor signalling and harbours genetic variation that is associated with prostate tumour aggressiveness
  13. Kallikrein-related peptidase signaling in colon carcinoma cells: targeting proteinase-activated receptors
  14. Proteinase-activated receptors (PARs): differential signalling by kallikrein-related peptidases KLK8 and KLK14
  15. Masthead
  16. Masthead
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 7.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/hsz-2011-0260/html
Scroll to top button